reduce basal insulin dose when starting glp-1 receptor agonist agonists and beyond. Part 1: benefits in type 2 diabetes GLP-1 receptor agonists in the

Semaglutide is a once weekly subcutaneous injection, gradually titrated by your provider and documented in your patient portal

See if you qualify

Methods This is a cohort study combining several population-wide databases and covering a Spanish population of five million inhabitants, including all adults with obesity who initiated treatment with either GLP-1RA or SGLT-2i for type 2 diabetes from 2015 to 2021

Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios

The science, promise and clinical development of GLP-1 and GIP receptor agonists in obesity

Learn what the evidence shows about muscle symptoms with semaglutide, tirzepatide, and other GLP-1 medications, plus when to contact your doctor and how to protect muscle mass during treatment.